MEDFORD, Mass.--ArQule, a drug discovery chemistry company here, will collaborate with Seattle biopharmaceutical Immunex to discover and develop products for the treatment of inflammatory disorders. Immunex will gain access to ArQule's mapping array program, comprised of libraries of novel, diverse, small organic, pure compounds used for screening against biological targets in new product discovery. Immunex will use the program to identify small molecule therapeutics based on a chemokine gene discovered by the Seattle company.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.